Asparaginases include asparaginase derived fromEscherichia coliorcarotovora,and pegasparaginase. Compared with the former two, pegasparaginase has the advantages of longer half-lifein vivoand lower immunogenicity, so it has become the first choice for the treatment of acute lymphoblastic leukemia (ALL) in children.However, during the clinical application of pegasparaginase to treat children with ALL, silent inactivation of pegasparaginase may occur, which leads to ineffective treatment of ALL children, and affects their prognosis seriously.Although the silent inactivation of pegasparaginase is a subclinical hypersensitivity reaction, compared with hypersensitivity, it has a certain degree of concealment, which is hard to identify.This article introduces the latest research progress in the definition, mechanism, epidemiological characteristics, hazards and treatment measures of silent inactivation of pegasparaginase in the treatment of ALL in children, in order to find effective methods to identify and treat silent inactivation of pegasparaginase.
